ArticleThe Journal of biological chemistry2026
Identification and characterization of inhibitors of the tuberculosis phosphatase PstP.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Tuberculosis is the leading infectious killer worldwide, with two billion infections and 1.25 million annual deaths. Antibiotic resistance drives prolonged, failure-prone treatments, underscoring the need for drugs with new mechanisms. Mycobacterial growth signaling pathways are promising targets. The Mycobacterium tuberculosis kinase PknB and phosphatase PstP are essential for growth and virulence. PknB inhibition sensitizes mycobacteria to β-lactams, and we hypothesized that concurrent PstP inhibition would enhance this effect. High-throughput screening identified 126 biochemical PstP inhibitors, four of which showed appreciable growth inhibition. These inhibitors acted additively with PknB inhibitors and displayed enhanced additive effects with β-lactams. PstP inhibition alone was bacteriostatic but antagonized β-lactam activity, consistent with on-target activity. PstP inhibition was additive with kinase inhibition, and inhibition of PstP and PknB with the addition of a β-lactam showed enhanced activity, with some treatment combinations even becoming bactericidal. PstP inhibitors showed low cytotoxicity, low apoptotic activity, and minimal host-cell phosphoprotein effects. Combinatorial treatments have IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.